81.32USD+1.10%Mkt Cap: 6.11B USDP/E: —Last update: 2026-06-01
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other infla…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap6.11B USD
Enterprise Value5.10B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-255.84M USD
Revenue/Share—
Last Price81.32 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees261
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.73
PEG—
EV/EBITDA-16.81
EV/Revenue—
P/S—
P/B4.87
EPS (TTM)-4.33
EPS (Forward)-5.22
52W Range
34.3477% of range95.32
52W High95.32 USD
52W Low34.34 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-28.30%
ROA-27.30%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-227.45M USD
CapEx (TTM)5.15M USD
FCF Margin—
FCF Yield-2.33%
Net Debt-1.05B USD
Net Debt/EBITDA3.46
Balance Sheet
Debt/Equity0.01
Current Ratio32.59
Quick Ratio32.38
Book Value/Sh16.87 USD
Cash/Share14.14 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)118.47 USD
Target Range81.00 USD – 160.00 USD
# Analysts17
Ownership
Shares Out.61.90M
Float57.83M
Insiders9.68%
Institutions131.04%
Short Interest
Short Ratio14.6d
Short % Float19.59%
Short % Out.12.43%
Shares Short9.37M
Short (prev mo.)9.57M
Technical
SMA 5082.55 (-1.5%)
SMA 20065.76 (+23.7%)
Beta0.69
S&P 52W Chg27.94%
Avg Vol (30d)683.57K
Avg Vol (10d)1.03M
Technical Indicators
RSI (14)46.9
MACD-1.0020
MACD Signal-0.6602
MACD Hist.-0.3418
BB Upper86.01 USD
BB Middle81.73 USD
BB Lower77.45 USD
BB Width10.47%
ATR (14)4.243 USD
Vol Ratio (20d)0.85x